Vertex Pharmaceuticals (VRTX) reported $12.0B in revenue for fiscal 2025, +8.9% year on year. That ranks #451 by revenue among 2853 SEC filers and #47 in Healthcare. Net income was $4.0B, a net margin of 32.9%. Revenue has grown 16.5% a year on average since 2011 ($1.4B then). The fiscal 2025 balance sheet shows $25.6B in total assets and $5.1B in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $12.0B | +8.9% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $4.2B | +$4.4B | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $4.0B | +$4.5B | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $3.6B | +$4.1B | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $438M | +47.0% | FY20252025-12-31 |
| Total assetsAssets | $25.6B | +13.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $18.7B | +13.7% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $5.1B | +11.3% | FY20252025-12-31 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $3.0B | $1.0B | Open → |
| Q2 20262026-06-30 | $3.3B | $1.1B | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 7 of 161 companies compared | 32.9% | |
| Operating marginRank 9 of 160 companies compared | 34.8% | |
| R&D as share of revenueRank 13 of 102 companies compared | 32.6% | |
| Cash as share of revenueRank 14 of 160 companies compared | 42.4% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Vertex Pharmaceuticals Inc
- Ticker
- VRTX
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0000875320
Filings
- 10-QAug 4, 2026Open filing →
- 10-QMay 5, 2026Open filing →
- 10-KFeb 13, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Unum GroupUNM | $13.1B | $739M |
| Brightspring Health ServicesBTSG | $12.9B | $189M |
| Community Health SystemsCYH | $12.5B | $509M |
| Vertex PharmaceuticalsVRTX | $12.0B | $4.0B |
| Oscar HealthOSCR | $11.7B | −$443M |
| Baxter InternationalBAX | $11.2B | −$957M |
| Quest DiagnosticsDGX | $11.0B | $992M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Vertex Pharmaceuticals — Key figures |url=https://companiesranked.com/en/company/vertex-pharmaceuticals |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Vertex Pharmaceuticals — Key figures. CompaniesRanked. https://companiesranked.com/en/company/vertex-pharmaceuticalsBibTeX
@misc{companiesranked-en-company-vertex-pharmaceuticals-2026,
author = {{CompaniesRanked}},
title = {{Vertex Pharmaceuticals — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/vertex-pharmaceuticals}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000875320-26-000056 · February 13, 2026
{{cite web |title=Vertex Pharmaceuticals — Key figures — 10-K (0000875320-26-000056) |url=https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-13}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.